Evidence map›Paper›PMID 39167113›Full record

ReviewCalcified tissue international2024

Skeletal and Non-skeletal Phenotypes in Children with Osteogenesis Imperfecta.

Juliana Marulanda, Jean-Marc Retrouvey, Frank Rauch

Abstract readReview
PubMed Publisher
In one paragraph

Review in Calcified tissue international, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. What's New in Osteogenesis Imperfecta.Journal of the Pediatric Orthopaedic Society of North America · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Juliana MarulandaShriners Hospital for Children - Canada, 1003 Decarie, Montreal, QC, H4A 0A9, Canada.
Jean-Marc RetrouveyBaylor College of Medicine, Houston, TX, USA.
Frank RauchShriners Hospital for Children - Canada, 1003 Decarie, Montreal, QC, H4A 0A9, Canada. frank.rauch@mcgill.ca.ORCID 0000-0002-6261-0360

Funding

Project 3: 3D ImagingU54AR068069 · NIAMS · BAYLOR COLLEGE OF MEDICINE · PI Brendan Lee · 2014 to 2026
$19.3M
NIAMS NIH HHS U54 AR068069
6 · The paper itself

Abstract

Although fractures are the defining characteristic of osteogenesis imperfecta (OI), the disorder affects many tissues. Here we discuss three facets of the OI phenotype, skeletal growth and development, skeletal muscle weakness and the dental and craniofacial characteristics. Short stature is almost universal in the more severe forms of OI and is probably caused by a combination of direct effects of the underlying genetic defect on growth plates and indirect effects of fractures, bone deformities and scoliosis. Recent studies have developed OI type-specific growth curves, which allow determining whether a given child with OI grows as expected for OI type. Impaired muscle function is an important OI-related phenotype in severe OI. Muscles may be directly affected in OI by collagen type I abnormalities in muscle connective tissue and in the muscle-tendon unit. Indirect effects like bone deformities and lack of physical activity may also contribute to low muscle mass and function. Dental and craniofacial abnormalities are also very common in severe OI and include abnormal tooth structure (dentinogenesis imperfecta), malocclusion, and deformities in the bones of the face and the skull. It is hoped that future treatment approaches will address these OI-related phenotypes.

Indexed as

Osteogenesis ImperfectaPhenotypeBone and BonesBone DevelopmentChildCraniofacial AbnormalitiesHumansMuscle, SkeletalMuscle WeaknessDentinogenesis imperfectaMalocclusionMuscle weaknessOsteogenesis imperfectaShort stature

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.